Chemoprevention in hereditary colorectal cancer syndromes

Reagan M. Barnett, Ester Borras, N. Jewel Samadder, Eduardo Vilar

Research output: Chapter in Book/Report/Conference proceedingChapter


Patients and families diagnosed with hereditary colorectal cancer syndromes present with an accelerated carcinogenesis. In this scenario, screening measures and preventive interventions play a crucial role in modulating the cancer risk by decreasing its incidence and mortality. In this chapter we will provide an overview of the clinical evidence of chemopreventive interventions developed in Familial Adenomatous Polyposis and Lynch Syndrome. Specifically, we will present the use of non-steroidal anti-inflammatory drugs (NSAIDs), which have been the most commonly studied agents in this field. Finally, we will discuss the latest clinical trials deploying targeted agents and modern NSAIDs in the context of prevention of hereditary colorectal cancer syndromes.

Original languageEnglish (US)
Title of host publicationHereditary Colorectal Cancer
Subtitle of host publicationGenetic Basis and Clinical Implications
PublisherSpringer International Publishing
Number of pages17
ISBN (Electronic)9783319742595
ISBN (Print)9783319742588
StatePublished - Jan 1 2018


  • Aspirin
  • Chemoprevention
  • Cox-2 inhibitors
  • Familial adenomatous polyposis
  • Hereditary colorectal cancer syndromes
  • Lynch syndrome
  • Nonsteroidal anti-inflammatory drugs

ASJC Scopus subject areas

  • General Medicine
  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Chemoprevention in hereditary colorectal cancer syndromes'. Together they form a unique fingerprint.

Cite this